Here is the design of a clinical trial:

Official Title: Effects of Prebiotic Supplementation and Exercise on Inflammatory Markers, Vascular Function, Cognition, and Mental Well-being in Pre-Dialysis Kidney Patients

Included conditions:
- Chronic Kidney Diseases

Study Armgroups:
- {'label': 'Exercise', 'type': 'EXPERIMENTAL', 'description': 'Exercise only: Patients randomized to this group will receive a placebo (corn starch) and be given 16 weeks of personal training.', 'interventionNames': ['Behavioral: Exercise']}
- {'label': 'Resistant Starch', 'type': 'EXPERIMENTAL', 'description': 'Resistant starch only: Patients randomized to this group will receive 30 g of resistant starch daily for 16 weeks. They will not be given an exercise training', 'interventionNames': ['Dietary Supplement: Resistant starch']}
- {'label': 'Exercise & Resistant Starch', 'type': 'EXPERIMENTAL', 'description': 'Exercise \\& resistant starch: Patients assigned to this group will do 16 weeks of personal training and they will be supplemented with 30 g of resistant starch daily for the 16 week period', 'interventionNames': ['Dietary Supplement: Resistant starch', 'Behavioral: Exercise']}
- {'label': 'Starch', 'type': 'PLACEBO_COMPARATOR', 'description': 'Corn starch only: Patients assigned to this group will not be given and exercise program and they will receive the placebo for 16 weeks', 'interventionNames': ['Behavioral: Starch']}

Interventions:
- {'type': 'DIETARY_SUPPLEMENT', 'name': 'Resistant starch', 'description': 'Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion', 'armGroupLabels': ['Exercise & Resistant Starch', 'Resistant Starch']}
- {'type': 'BEHAVIORAL', 'name': 'Exercise', 'description': 'Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity', 'armGroupLabels': ['Exercise', 'Exercise & Resistant Starch']}
- {'type': 'BEHAVIORAL', 'name': 'Starch', 'description': 'Patients will be given 30 grams of corn starch', 'armGroupLabels': ['Starch']}

Primary Outcomes:
- {'measure': 'Change in hs CRP', 'description': 'hsCRP', 'timeFrame': 'baseline and after 16 weeks'}
- {'measure': 'Change in TNF alpha', 'description': 'TNFalpha', 'timeFrame': 'Baseline and at week 16'}
- {'measure': 'Change in IL6', 'description': 'IL6', 'timeFrame': 'Baseline and at week 16'}
- {'measure': 'Change in IL10', 'description': 'IL10', 'timeFrame': 'Baseline and at week 16'}
- {'measure': 'Change in MCP1', 'description': 'MCP1', 'timeFrame': 'Baseline and at week 16'}

Please estimate the sample size based on the assumption: 
Power set at 0.80, alpha set at 0.05, multiple imputation for missing data, per-protocol analysis for participants completing 70% or more of their assigned tasks.
Sample size estimates
        A study investigating the effects of aerobic exercise on inflammation reduction [24] demonstrated effect sizes (Cohenâs d) varying between .40 and .77 for IL-6 and IL-10 and their ratio, which would be considered a medium to large effect. Few studies have investigated the effect of prebiotic supplements on inflammation, though similar magnitude effect sizes were reported for a prebiotic supplement intervention on changes in free circulating uremic solutes indoxyl sulfate and p-cresol sulfate, key indicators of adverse outcomes of CKD [9], though those changes were not found to be significant in that small sample study. Based on these studies, we anticipate medium effect sizes, and with power set at .80, and alpha set at .05, a sample size of 60 (15 per group) is predicted to be sufficient for detecting significant two-way interactions specified in the statistical analysis section. To account for any dropouts from the protocol, missing data will be addressed through multiple imputation, and results of all analyses averaged over multiple imputed datasets. All variables in the analysis will be examined for assumptions for all statistical tests. Data will also be examined in a per-protocol analysis, using only data from participants in all groups who completed 70% or more of their assigned exercise sessions and/or supplement use and who provided outcome data on the relevant variables.